Prescription Drug News and Research

RSS

Viewpoints: Health care and the 'crushing federal debt;' Optimism about 'grand bargain;' Iowa's premium increase request

The largest issue America will face in 2013 is health care. And it will only get larger. As the national conversation changes, we'll find that by year-end we're talking about it all the time, whether the ostensible topic is politics, government, the economy, our jobs, or our families. Health care will be the unavoidable topic. Medicare and Medicaid are the biggest element of our most serious national problem: crushing federal debt.

9 Jan 2013

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

3 Jan 2013

Longer looks: DIY abortions and the law; Helping other parents reach out to mentally ill children; Human growth hormone and Big Pharma

McCormack knew that an abortion would cost $400 to $2,000, depending on how far along she was. ... She couldn't come up with that kind of money. So she called her older sister, who owned a computer, and asked her to order abortion pills for her on the Internet.

3 Jan 2013

Roundup: Medicaid waiver challenges in Texas; Detailing Sandy's impact on NYC's mental care

By 2012's end, health care providers across Texas will have submitted proposals to state leaders to transform the way they care for the poor and uninsured. They have been spurred by a Medicaid waiver Texas officials sought and received in 2011 from the federal government, one that ties financing to cooperation, cost efficiency and better patient outcomes.

2 Jan 2013

Viewpoints: Playing chicken on entitlements; 'Getting serious' about mental illness; Hospital labs devastated by Sandy

This is no time for a Grand Bargain, because the Republican Party, as now constituted, is just not an entity with which the president can make a serious deal. If we're going to get a grip on our nation's problems - of which the budget deficit is a minor part - the power of the G.O.P.'s extremists, and their willingness to hold the economy hostage if they don't get their way, needs to be broken. And somehow I don't think that's going to happen in the next few days (Paul Krugman, 12/20).

21 Dec 2012

Maneuvering toward a 'fiscal cliff' deal

Despite progress toward an agreement with the White House, House Republicans appeared to veer off course Tuesday with a "Plan B" if budget talks fail. Some media outlets suggested that both President Barack Obama and Speaker John Boehner, R-Ohio, are attempting to quell backlash within their own parties -- Boehner for agreeing to tax increases, Obama for ceding some entitlement cuts.

20 Dec 2012

NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan.

20 Dec 2012

Survey shows health care costs projected to increase at slower pace

Projected cost increases for all types of medical plans are anticipated to be down by between 0.2 and 0.6 percent through the first half of 2013, according to a survey by Buck Consultants, A Xerox Company.

17 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength.

12 Dec 2012

As clock ticks toward fiscal deadline, Obama, Boehner meet at the White House

Action this week is critical if a deal is to be reached this year, The Washington Post reports. Most analysts appear to agree that the contours of such an agreement are clear, but the specifics -- which include raising taxes as well as spending reductions for Medicare and Medicaid -- remain challenging and politically divisive.

10 Dec 2012

GOP Sen. Corker says party should accept tax hikes to get spending cuts

As pressure builds for a "fiscal cliff" deal, several key players talked about strategy on the Sunday morning news shows. Meanwhile, Politico reports that Republicans' hope of a big victory on cutting entitlement spending has dimmed while The Hill looks at Democrats' new willingness to consider means testing for Medicare.

9 Dec 2012

Roundup: Ga. 'provider fee' defeat could mean $430M less for Medicaid; Minn. health programs in line for $37M cut over fiscal cliff; Calif. stem cell board criticized

Just weeks before the 2013 General Assembly convenes, the state's provider fee, called a "bed tax" by some, remains a high-profile wild card -- one that could deal Georgia's hospital industry a crippling blow. If the fee is not renewed -- and anti-tax forces will oppose it -- the Medicaid system may lose $430 million-plus that the assessment now generates. That loss would swell the state's Medicaid financial shortfall, which is already about $400 million (Miller, 12/6).

7 Dec 2012

Viewpoints: Considering baby boomers' future burden on Medicare; Holtz-Eakin endorses state exchanges; The value (or not) of mammograms

The Congressional Budget Office projects that if current policies continue, total federal spending will rise to 24 percent of gross domestic product in 2022. [Republicans and Washington deficit hawks'] proposed solution is a cap on government spending.

7 Dec 2012

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

First Edition: December 6, 2012

Today's headlines include a report that some in the GOP are urging lawmakers to support the idea of trading tax breaks for changes in safety-net programs.

6 Dec 2012

Government announces fraud collections hit record $5 billion

The Justice Department's civil division recovered a record $5 billion in the past fiscal year from companies that defrauded taxpayers, with much of the abuse occurring in the health care and mortgage industries.

6 Dec 2012

Studies gauge health law's impact on consumer savings, Rx drug coverage

The Commonwealth Fund concluded that consumers saved $1.5 billion in 2011 as a result of a provision that limits how much insurers can spend on expenses not related to medical care. Meanwhile, Avalere Health found that drug coverage plans offered on health exchanges will vary by state.

6 Dec 2012

Prescribing opioids lead to admissions for substance abuse treatment and deaths

A Viewpoint article published recently in the Journal of the American Medical Association suggests that the clinical practice of prescribing amphetamines, opioids, and benzodiazepines to treat chronic pain may be contributing to the increase in fatal drug overdoses and the likelihood that those drugs will be diverted to the illegal market.

6 Dec 2012